- Home
- Publications
- Publication Search
- Publication Details
Title
Advances in Universal CAR-T Cell Therapy
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-10-07
DOI
10.3389/fimmu.2021.744823
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Allogeneic CAR Cell Therapy—More Than a Pipe Dream
- (2021) Kenneth J. Caldwell et al. Frontiers in Immunology
- Proof-of-concept for Rapidly Switchable Universal CAR-T Platform with UniCAR-T-CD123 in Relapsed/Refractory AML
- (2021) Martin Wermke et al. BLOOD
- CRISPR/Cas9-engineered universal CD19/CD22 dual-targeted CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia
- (2021) Yongxian Hu et al. CLINICAL CANCER RESEARCH
- Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma
- (2021) Darel Martínez Bedoya et al. Frontiers in Immunology
- Off-the-Shelf Chimeric Antigen Receptor T Cells
- (2021) Norihiro Watanabe et al. CANCER JOURNAL
- Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells
- (2021) Bo Wang et al. Nature Biomedical Engineering
- Interleukin-23 engineering improves CAR T cell function in solid tumors
- (2020) Xingcong Ma et al. NATURE BIOTECHNOLOGY
- ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges
- (2020) S. Depil et al. NATURE REVIEWS DRUG DISCOVERY
- Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
- (2020) Enli Liu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Joint profiling of chromatin accessibility and CAR-T integration site analysis at population and single-cell levels
- (2020) Wenliang Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Toward an Optimized Process for Clinical Manufacturing of CAR-Treg Cell Therapy
- (2020) Enrico Fritsche et al. TRENDS IN BIOTECHNOLOGY
- Human chimeric antigen receptor macrophages for cancer immunotherapy
- (2020) Michael Klichinsky et al. NATURE BIOTECHNOLOGY
- Cancer cell therapies: the clinical trial landscape
- (2020) Jia Xin Yu et al. NATURE REVIEWS DRUG DISCOVERY
- Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy
- (2020) Yuki Kagoya et al. Cancer Immunology Research
- The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice
- (2020) Marco Cerrano et al. Frontiers in Immunology
- Rapidly Switchable Universal CAR-T cells for Treatment of CD123-positive Leukemia
- (2020) Simon Loff et al. Molecular Therapy-Oncolytics
- Recent advances in CAR-T cell engineering
- (2020) Ruihao Huang et al. Journal of Hematology & Oncology
- Engineered off-the-shelf therapeutic T cells resist host immune rejection
- (2020) Feiyan Mo et al. NATURE BIOTECHNOLOGY
- Use of Cell and Genome Modification Technologies to Generate Improved “Off-the-Shelf” CAR T and CAR NK Cells
- (2020) Michael A. Morgan et al. Frontiers in Immunology
- Modular Chimeric Antigen Receptor Systems for Universal CAR T Cell Retargeting
- (2020) Ashley R. Sutherland et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis
- (2020) Andras Heczey et al. NATURE MEDICINE
- CAR-NK cells: A promising cellular immunotherapy for cancer
- (2020) Guozhu Xie et al. EBioMedicine
- Eradication of T-ALL cells by CD7 targeted universal CAR-T cells and initial test of ruxolitinib-based CRS management
- (2020) Shiqi Li et al. CLINICAL CANCER RESEARCH
- Chimeric antigen receptor‐modified macrophages trigger systemic anti‐tumour immunity
- (2020) Zhiyuan Niu et al. JOURNAL OF PATHOLOGY
- Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
- (2020) Reuben Benjamin et al. LANCET
- Broad Cytotoxic Targeting of Acute Myeloid Leukemia by Polyclonal Delta One T Cells
- (2019) Biagio Di Lorenzo et al. Cancer Immunology Research
- Chimeric antigen receptor engineered innate immune cells in cancer immunotherapy
- (2019) Chu Lin et al. Science China-Life Sciences
- Induced Pluripotent Stem Cell (iPSC)–Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and Challenges
- (2019) Alexandros Nianias et al. Current Hematologic Malignancy Reports
- Conventional CARs versus modular CARs
- (2019) Anja Feldmann et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- NKT cells co-expressing a GD2-specific chimeric antigen receptor and IL-15 show enhanced in vivo persistence and antitumor activity against neuroblastoma
- (2019) Xin Xu et al. CLINICAL CANCER RESEARCH
- Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity
- (2019) Shengnan Yu et al. Molecular Cancer
- Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies
- (2019) Zsolt Sebestyen et al. NATURE REVIEWS DRUG DISCOVERY
- CAR-NK for tumor immunotherapy: Clinical transformation and future prospects
- (2019) Wenxiu Wang et al. CANCER LETTERS
- Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies
- (2019) Mathew L. Cooper et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Mechanisms of resistance to CAR T cell therapies
- (2019) Nathan Singh et al. SEMINARS IN CANCER BIOLOGY
- Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities
- (2018) Ling Li et al. BIOMATERIALS
- Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses
- (2018) Jang Hwan Cho et al. CELL
- Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity
- (2018) Ye Li et al. Cell Stem Cell
- Correction to: Gamma-delta (γδ) T cells: friend or foe in cancer development?
- (2018) Yijing Zhao et al. Journal of Translational Medicine
- Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation
- (2018) Anna Capsomidis et al. MOLECULAR THERAPY
- Chimeric Antigen Receptor Therapy
- (2018) Carl H. June et al. NEW ENGLAND JOURNAL OF MEDICINE
- Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy
- (2018) Benjamin J. Wolf et al. Frontiers in Immunology
- Programming CAR-T cells to kill cancer
- (2018) Louai Labanieh et al. Nature Biomedical Engineering
- Off-the-Shelf CAR-NK Cells for Cancer Immunotherapy
- (2018) Elizabeth L. Siegler et al. Cell Stem Cell
- CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment
- (2018) Hasan Mollanoori et al. HUMAN IMMUNOLOGY
- The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma
- (2018) Bianca Simon et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia
- (2018) John K. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
- (2018) Marco Ruella et al. NATURE MEDICINE
- Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
- (2018) Jennifer N. Brudno et al. BLOOD REVIEWS
- A retrospective comparison of allogenic and autologous chimeric antigen receptor T cell therapy targeting CD19 in patients with relapsed/refractory acute lymphoblastic leukemia
- (2018) Yongxian Hu et al. BONE MARROW TRANSPLANTATION
- Universal CARs, universal T cells, and universal CAR T cells
- (2018) Juanjuan Zhao et al. Journal of Hematology & Oncology
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance
- (2018) Qunfang Zhang et al. Frontiers in Immunology
- A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization
- (2017) Esther Drent et al. MOLECULAR THERAPY
- Engineering Natural Killer Cells for Cancer Immunotherapy
- (2017) Katayoun Rezvani et al. MOLECULAR THERAPY
- Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
- (2017) Justin Eyquem et al. NATURE
- Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity
- (2017) Arnab Ghosh et al. NATURE MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
- (2017) Waseem Qasim et al. Science Translational Medicine
- Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition
- (2016) Jiangtao Ren et al. CLINICAL CANCER RESEARCH
- Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease
- (2016) Jennifer N. Brudno et al. JOURNAL OF CLINICAL ONCOLOGY
- Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts
- (2016) M Cartellieri et al. Blood Cancer Journal
- Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD
- (2015) E. Jacoby et al. BLOOD
- Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies
- (2015) Laurent Poirot et al. CANCER RESEARCH
- TRUCKs: the fourth generation of CARs
- (2015) Markus Chmielewski et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy
- (2015) Julien Valton et al. MOLECULAR THERAPY
- Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia
- (2015) Hanren Dai et al. OncoImmunology
- Induced Pluripotent Stem Cells: Challenges and Opportunities for Cancer Immunotherapy
- (2014) Patty Sachamitr et al. Frontiers in Immunology
- Harnessing the antitumor potential of macrophages for cancer immunotherapy
- (2014) Kristen B Long et al. OncoImmunology
- Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation
- (2013) J. N. Kochenderfer et al. BLOOD
- Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy
- (2013) Maria Themeli et al. NATURE BIOTECHNOLOGY
- Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo
- (2013) E. Lanitis et al. Cancer Immunology Research
- A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR
- (2012) H. Torikai et al. BLOOD
- A Universal Strategy for Adoptive Immunotherapy of Cancer through Use of a Novel T-cell Antigen Receptor
- (2012) K. Urbanska et al. CANCER RESEARCH
- Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells
- (2012) Christopher C Kloss et al. NATURE BIOTECHNOLOGY
- The promise and potential pitfalls of chimeric antigen receptors
- (2009) Michel Sadelain et al. CURRENT OPINION IN IMMUNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started